NCT02561455 Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial Status COMPLETED Phase PHASE1/PHASE2
NCT02560025 Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML Status COMPLETED Phase PHASE2
NCT02544438 Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE1/PHASE2
NCT02543879 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Status COMPLETED Phase PHASE1
NCT02530476 Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia Status COMPLETED Phase PHASE1/PHASE2
NCT02527447 Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15) Status COMPLETED Phase N/A
NCT02521493 Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02508324 IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia Status TERMINATED Phase PHASE2
NCT02508038 Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors Status RECRUITING Phase PHASE1
NCT02500550 Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor Status COMPLETED Phase PHASE2
NCT02498665 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Status COMPLETED Phase PHASE1
NCT02494167 Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02488408 A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS Status COMPLETED Phase PHASE1/PHASE2
NCT02485535 Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Status COMPLETED Phase PHASE1
NCT02483312 A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML) Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02474290 Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML Status COMPLETED Phase PHASE2/PHASE3
NCT02473146 Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 Status COMPLETED Phase PHASE2/PHASE3
NCT02464657 Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Status COMPLETED Phase PHASE1/PHASE2